The Role of m6A RNA Modification in Moyamoya Disease

Moyamoya Disease Clinical Trial

Official title:

The Role of m6A RNA Modification in Moyamoya Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04696094
• Other study ID #: KY 2020-118-03
• Status: Recruiting
• Start date: January 1, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2022
• Source: Beijing Tiantan Hospital
• Contact: Qian Zhang, MD
• Phone: 008613611075005
• Email: zhangqianchina[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to detect the change of m6A RNA modification from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.

Description:

Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by occlusion of bilateral internal carotid and intracerebral arteries with the compensatory growth of fragile small vessels. The etiology of disease is still unclear. The pathology is associated with blood vessels, characterizing the molecular changes of blood in patients with MMD may yield insights into the disease. N6-methyladenosine (m6A) is identified to be the most common and abundant RNA molecular modification in eukaryotes, and involves in a variety of metabolic processes of RNA, such as RNA transcription, shearing, nuclear transport, and translation ability. The propose of this study is to investigate the change of m6A RNA modification in patients blood with moyamoya disease and its influence on clinical indicators, aiming to provide potential pathogenesis of moyamoya disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 60 Years

Eligibility

Health volunteers' inclusion criteria:

Age between 4-60; Male or female; Exclusion criteria: Exclude the volunteers with history of cerebrovascular disease.

Related Conditions & MeSH terms

• Moyamoya Disease

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	m6A RNA modification in peripheral blood	m6A RNA modification in peripheral blood	2021.1.1-2021.12.31
Secondary	Suzuki grade	Stage 1 stenosis of the carotid artery at its suprasellar portion, usually bilateral; Stage 2 moyamoya vessels begin to develop at the base of the brain; Stage 3 moyamoya vessels become more prominent as major trunks in the anterior circulation become severely stenotic or occluded; Stage 4 posterior cerebral arteries are occluded, moyamoya vessels begin to diminish and collateral pathways from extracranial circulation develop; Stage 5, moyamoya vessels are diminishing and extracranial circulation progresses; Stage 6, moyamoya vessels and the major cerebral arteries completely disappear, the cerebral hemispheres receive blood through the abnormal extracranial-intracranial anastomosis.; Higher scores mean a worse outcome.	30days
Secondary	Modified Rankin Scale score	0 No symptoms at all; 1 No significant disability despite symptoms, able to carry out all usual duties and activities; 2 Slight disability, unable to carry out all previous activities, but able to look after own affairs without assistance; 3 Moderate disability, requiring some help, but able to walk without assistance; 4 Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance; 5 Severe disability, bedridden, incontinent and requiring constant nursing care and attention.; Higher scores mean a worse outcome.	6months
Secondary	New clinical vascular events	New clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA)	6 months